Recent developments and translational aspects in targeted therapy for metastatic breast cancer

Biologically distinct subtypes of metastatic breast cancer (MBC) have been defined by multiple efforts in recent years, showing broad heterogeneity at the molecular level of disease. Throughout this endeavour, oncogenic drivers within MBC were identified as potential therapeutic targets. With recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Marhold, Maximilian, Bartsch, Rupert, Zielinski, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070263/
https://www.ncbi.nlm.nih.gov/pubmed/27843605
http://dx.doi.org/10.1136/esmoopen-2016-000036
_version_ 1782461109852176384
author Marhold, Maximilian
Bartsch, Rupert
Zielinski, Christoph
author_facet Marhold, Maximilian
Bartsch, Rupert
Zielinski, Christoph
author_sort Marhold, Maximilian
collection PubMed
description Biologically distinct subtypes of metastatic breast cancer (MBC) have been defined by multiple efforts in recent years, showing broad heterogeneity at the molecular level of disease. Throughout this endeavour, oncogenic drivers within MBC were identified as potential therapeutic targets. With recent results from clinical trials targeting these well-known cancer-promoting pathways, this review is trying to elucidate as well as summarise current new therapeutic aspects in MBC and shed light on translational aspects within this entity.
format Online
Article
Text
id pubmed-5070263
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50702632016-11-14 Recent developments and translational aspects in targeted therapy for metastatic breast cancer Marhold, Maximilian Bartsch, Rupert Zielinski, Christoph ESMO Open Review Biologically distinct subtypes of metastatic breast cancer (MBC) have been defined by multiple efforts in recent years, showing broad heterogeneity at the molecular level of disease. Throughout this endeavour, oncogenic drivers within MBC were identified as potential therapeutic targets. With recent results from clinical trials targeting these well-known cancer-promoting pathways, this review is trying to elucidate as well as summarise current new therapeutic aspects in MBC and shed light on translational aspects within this entity. BMJ Publishing Group 2016-05-04 /pmc/articles/PMC5070263/ /pubmed/27843605 http://dx.doi.org/10.1136/esmoopen-2016-000036 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Review
Marhold, Maximilian
Bartsch, Rupert
Zielinski, Christoph
Recent developments and translational aspects in targeted therapy for metastatic breast cancer
title Recent developments and translational aspects in targeted therapy for metastatic breast cancer
title_full Recent developments and translational aspects in targeted therapy for metastatic breast cancer
title_fullStr Recent developments and translational aspects in targeted therapy for metastatic breast cancer
title_full_unstemmed Recent developments and translational aspects in targeted therapy for metastatic breast cancer
title_short Recent developments and translational aspects in targeted therapy for metastatic breast cancer
title_sort recent developments and translational aspects in targeted therapy for metastatic breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070263/
https://www.ncbi.nlm.nih.gov/pubmed/27843605
http://dx.doi.org/10.1136/esmoopen-2016-000036
work_keys_str_mv AT marholdmaximilian recentdevelopmentsandtranslationalaspectsintargetedtherapyformetastaticbreastcancer
AT bartschrupert recentdevelopmentsandtranslationalaspectsintargetedtherapyformetastaticbreastcancer
AT zielinskichristoph recentdevelopmentsandtranslationalaspectsintargetedtherapyformetastaticbreastcancer

Ejemplares similares